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soluble A      levels in hemibrain homogenates were not sig-
nificantly different between immunized and control mice. 
Microhemorrhage was not observed with anti-pE3-A      im-
munotherapy.   Conclusions:   Selective removal of pE3-A     
lowered general A    plaque deposition suggesting a pro-ag-
gregation or seeding role for pE3-A    . 
  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
  Alzheimer’s disease (AD), the most common form of 
dementia, afflicts more than 30 million people world-
wide. Amyloid-    protein (A   ) is implicated in AD patho-
genesis   [1]  . N-terminally truncated and pyroglutamate-
modified A      peptide starting at residue 3 (pE3-A    )  is 
abundant in cored and diffuse A    deposits as well as vas-
cular amyloid in AD, presenilin-linked familial AD, and 
Down syndrome brain   [2–6] .  pE3-A     is formed upon re-
moval of the first 2 N-terminal residues of A      followed 
by cyclization by glutaminyl cyclase (QC; isoQC) to con-
vert the third residue, glutamic acid, to pyroglutamate  [7] . 
Pyroglutamate formation makes A    peptide more hydro-
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 Abstract 
  Background:  N-terminally truncated and modified pyroglu-
tamate-3 amyloid-      protein (pE3-A     ) is present in most, if 
not all, cerebral plaque and vascular amyloid deposits in hu-
man Alzheimer’s disease (AD). pE3-A      deposition is also 
found in AD-like transgenic (tg) mouse brain, albeit in lesser 
quantities than general A    .  pE3-A     resists degradation, is 
neurotoxic, and may act as a seed for A    aggregation.  Objec-
tive:   We sought to determine if pE3-A      removal by passive 
immunization with a highly specific monoclonal antibody 
(mAb) impacts pathogenesis in a mouse model of Alzhei-
mer’s amyloidosis.   Methods:   APPswe/PS1    E9 tg mice were 
given weekly intraperitoneal injections of a new anti-pE3-A    
mAb (mAb07/1) or PBS from 5.8 to 13.8 months of age (pre-
vention) or from 23 to 24.7 months of age (therapeutic). Mul-
tiple forms of cerebral A      were quantified pathologically 
and biochemically. Gliosis and microhemorrhage were ex-
amined.  Results:  Chronic passive immunization with an anti-
pE3-A      mAb significantly reduced total plaque deposition 
and appeared to lower gliosis in the hippocampus and cer-
ebellum in both the prevention and therapeutic studies. In-
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phobic, speeding up its aggregation; pE3-A      peptide re-
sists degradation, favoring formation of stable, neurotox-
ic aggregates   [8–11]  . It is unclear if pE3-A      peptide is 
present in early plaque deposition or if it accrues later. 
However, a correlation has been reported between pyro-
glutamate-modified A      forms and severity of disease 
  [12–14]  . Taken together, these results indicate that pE3-
A      peptide plays an important role in AD pathogenesis. 
Thereby, the N-terminal truncation and modification 
makes this peptide species a superior target for immuni-
zation. The primary advantage of such a strategy might 
be to capture and detoxify a particular A    molecule with-
out affecting the potential physiological function of full-
length A   . Here, we used passive immunization targeting 
pE3-A      in AD-like transgenic (tg) mice to determine if 
selective removal of this toxic peptide impacts AD patho-
genesis.
  M e t h o d s  
 Antibody  Characterization 
  Western blot analysis was performed as described previously 
  [15] . The cross-reactivity was determined by surface plasmon res-
onance using a Biacore 3000. Different pyroglutamate-modified 
peptides were immobilized covalently on CM5 chips. The binding 
to these peptides was characterized by monitoring the association 
( 5 4 0  s )  a n d  d i s s o c i a t i o n  ( 5 4 0  s )  o f  t h e  m o n o c l o n a l  a n t i b o d y  
mAb07/1.
  A n i m a l s  
 APPswe/PS1    E9 mice   [16]  , harboring human APPswe 
(K595N/M596L) and PS1     E9 (deletion of exon 9), were obtained 
from Jackson Lab (Bar Harbor, Me., USA), and bred in our colony 
with C57BL/6 mice. All animal use was approved by the Harvard 
Standing Committee for Animal Use and was in compliance with 
all state and federal regulations. Cerebral A      plaque deposition 
and cerebral amyloid angiopathy are initiated at 5–6 months in 
this model   [17] .
  Passive  Immunization 
  Two trials were conducted in gender- and age-matched APP-
swe/PS1    E9 mice. A ‘prevention’ trial was initiated in 5.8-month-
old mice (  8  0.38 SEM; anti-pE3-A      mAb, n = 6; PBS control, n = 
3), during the early stage of plaque deposition, and continued for 
32 weeks. A ‘therapeutic’ trial was undertaken in 23-month-old 
mice (  8  0.25 SEM; anti-pE3-A     , n = 4; PBS control, n = 4) with 
robust cerebral A      and pE3-A      plaque deposition and cerebral 
amyloid angiopathy, and continued for 7 weeks. Mice were vac-
cinated weekly by intraperitoneal injection of 200      g of a new 
mouse IgG1 mAb specific for pE3-A    [mAb07/1; Probiodrug AG, 
Halle (Saale), Germany] or 100      l of PBS (as a control).
  T i s s u e   C o l l e c t i o n  
  Mice were sacrificed by CO  2   inhalation 1 week after the final 
immunization. Blood was collected via cardiac puncture followed 
by perfusion with 20 ml PBS. The brain was removed and divided 
sagitally. One hemibrain was fixed for 2 h in 10% neutral buffered 
formalin and processed for paraffin embedding while the other 
was snap frozen and stored at –80    °    C for biochemical analysis.
    Immunohistochemistry, Histology and Quantification 
  Ten-micrometer paraffin sections were immunolabeled using 
the ABC ELITE method (Vector Laboratories, Burlingame, Calif., 
USA) as previously described   [18]  . The following antibodies were 
used for immunohistochemical analysis: anti-CD45 (1:    5,000,  Se-
rotec, Raleigh, N.C., USA), anti-Iba-1 (1:     500, Wako Chemicals, 
Richmond, Va., USA), anti-GFAP (1:    1,000,  DakoCytoma-
tion, Carpinteria, Calif., USA), rabbit polyclonal anti-A      R1282 
(1:     1,000, gift from D. Selkoe, Boston, Mass., USA) and anti-pE3-
A      mAb07/1 [1:     1,000, gift from Probiodrug AG, Halle (Saale), 
Germany]. One-percent aqueous Thioflavin S (Sigma Aldrich, St. 
Louis, Mo., USA) was used to visualize fibrillar amyloid in plaques 
and blood vessels. Hemosiderin staining using 2% ferrocyanide 
(Sigma) in 2% hydrochloric acid was used to detect microhemor-
rhages. Quantification of total R1282 immunoreactivity (IR), 
pE3-A      IR and Thioflavin S staining was performed using
BIOQUANT image analysis (Nashville, Tenn., USA). The thresh-
old of detection was held constant during analysis. The percent 
area occupied by R1282 IR, pE3-A    IR or Thioflavin S labeling in 
the entire hippocampus and cerebellum was calculated for 3 equi-
distant sagittal sections 300      m apart per mouse. Vascular amy-
loid was evaluated semiquantitatively by 2 investigators (blinded 
to the treatment group) using the following criteria: ‘0’ = no posi-
tive blood vessels; ‘1’ = 1–5 positive blood vessels; ‘2’ = 6–10 posi-
tive blood vessels, and ‘3’ = 11 or more positive blood vessels.
    Brain Homogenates and ELISAs 
  Snap-frozen whole hemispheres were homogenized in 5 vol-
umes of Tris-buffered saline containing a protease inhibitor cock-
tail (Roche, Indianapolis, Ind., USA). Homogenates were spun at 
175,000   g   for 30 min at 4    °    C. The Tris-buffered saline pellet was 
resuspended in 10 volumes of guanidine buffer (5   M   guanidine 
HCl, 50 m  M   Tris, pH 8.0). Samples were mixed for 4 h at room 
temperature and stored at –20    °   C.  A    (x–42) and pE-A    (3–42) 
were quantified as previously described   [19]   using commercial 
ELISA kits (IBL, Hamburg, Germany).
  Statistical  Analyses 
  The Mann-Whitney U test (Prism 4.0 Software, GraphPad, 
San Diego, Calif., USA) was used to compare the results of immu-
nized and PBS control mice. Significant differences were defined 
as p   !   0.05.
  R e s u l t s  
 Anti-pE3-A     mAb Characterization 
  The specificity of antibody mAb07/1 was assessed by 
a combination of Western blot and surface plasmon reso-
nance analysis (  fig. 1   ). The antibody showed no cross-
reactivity with full-length A     (1–x) or truncated, non-
cyclized A   (3–x) in Western blot analyses. Moreover, py-
roglutamate-modified neuropeptides or hormones were  Passive  PyroGlu3-A     Immunotherapy in 
Mice 
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not recognized by mAb07/1, suggesting a very high spec-
ificity of the molecule without potential of side effects. 
For immunization, the antibody was purified from cul-
tures of mouse hybridoma cells and then sterile-filtered 
in PBS. The concentration range for injection was 2–2.5 
mg/ml.
  Passive  Anti-pE3-A     Vaccination Lowered Total A     
Deposition in a Prevention Trial 
 A     deposition begins in the hippocampus, neocortex 
and cerebellum at 5–6 months in APPswe/PS1    E9  mice 
and increases with age   [17]  . By 6 months, a small subset 
of mostly compacted plaques contains pE3-A     ; this sub-
set increases with age in proportion to general A      depo-
sition (data not shown). In this study, mice were immu-
nized weekly with the highly specific anti-pE3-A     
mAb07/1 starting at 5.8 months of age, during the early 
stages of A      deposition. Following 32 weeks of vaccina-
tion, total A      deposition (including plaques and cerebral 
amyloid angiopathy) was reduced in the hippocampus 
and cerebellum in the approximately 14 month-old treat-
ed mice compared to age- and gender-matched PBS con-
trols (  table 1  ;   fig. 2  ). In the hippocampus, pE3-A      and 
general A      (R1282) IR were reduced by 35% (p = 0.04) 
and 18% (p = 0.01), respectively, while Thioflavin-S-pos-
itive fibrillar amyloid was reduced by 50% (p = 0.02) in 
immunized mice when normalized to PBS controls. In 
the cerebellum, pE3-A      and general A      IR were lowered 
by 76% (p = 0.0004) and 52% (p = 0.005), respectively, 
while Thioflavin-S-positive fibrillar amyloid was 43% 
less (p = 0.13, n.s.) in immunized mice when normalized 
to the PBS control mice. The absolute values, listed in 
  table  1  , strongly suggest that passive immunization 
against pE3-A      reduced more than pE3-A      alone. For 
example, an absolute reduction of 2.4% in general A     
(R1282) IR was observed in the hippocampus, whereas 
the absolute amount of pE3-A      in the PBS control group 
was much lower (0.61%;   table 1  ). Similar reductions were 
observed in the cortex but were not quantified (data not 
shown). Semiquantitative analysis of vascular amyloid 
(scored 0–3) was similar in the hippocampus between 
PBS control and pE3-A    vaccinated mice (R1282: 0.89  8  
0.11 SEM vs. 0.59   8   0.12, p = 0.11; pE3-A     : 0 vs. 0, p = 
n.s.). In the cerebellum, vascular amyloid was reduced by 
vaccination (R1282: 2.11  8  0.26 vs. 1.47  8  0.15, p = 0.03; 
pE3-A     : 0.33   8   0.17 vs. 0.17   8   0.09, p = 0.24). Micro-
hemorrhages were absent in both groups of approximate-
ly 14-month-old mice.
    No significant differences between immunized and 
control mice were observed in pE-A     (3–42) and A    (x–
42) levels in guanidine HCl-extracted hemibrain homog-
enates; pE-A     (3–42) was approximately 0.2% of A    (x–
42). Microgliosis (Iba-1 and CD45 IR) and astrocytosis 
(GFAP IR) appeared to be attenuated in the immunized 
mice compared to PBS controls. 
  P a s s i v e   A n t i - p E 3 - A   Vaccination     Reduced Plaque 
Burden in the Absence of Microhemorrhage in a 
Therapeutic Trial 
  Twenty-three-month-old, plaque-bearing APPswe/
PS1     E9 mice were passively immunized weekly for 7 
weeks. The percent areas occupied by general A      IR and 
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  Fig. 1. Characterization of pE3-A      mAb07/1.   a   Western blot of 
A    (1–40),  A    (3–40) and pE3-A     (3–40), detected with mAb07/1 
or mAb6E10. Peptides (20 ng each) were separated in gels contain-
ing 8   M  urea. The anti-pE3-A    mAb does not detect the truncated 
precursor or full-length A   .  b  Analysis of antibody binding using 
surface plasmon resonance. The peptides were covalently linked 
and the antibody applied in a buffered solution. Significant bind-
ing of mAb07/1 was only observed with pE3-A    (3–40)  immobi-
lized on the surface. Other peptides analyzed are: MCP-1 and 2; 
gastrin; GnRH; neurotensin; orexin; TRH; the N-terminus of col-
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pE3-A      IR, respectively, were higher in the 24.7-month-
old versus 14-month-old PBS control mice at the end of 
each study, especially in the cerebellum (data not shown). 
Overall, therapeutic passive anti-pE3-A      immunization 
reduced both general A      and pE3-A      IR  ( table 1 ;   fig. 3 ), 
similar to the reductions seen in the prevention study. In 
the hippocampus, pE3-A      and general A      (R1282) IR 
were reduced by 34% (n.s.) and 25% (p = 0.03), respec-
tively, while Thioflavin-S-positive fibrillar amyloid was 
reduced by 49% (p = 0.04) in the immunized mice when 
normalized to the PBS control mice. In the cerebellum, 
pE3-A      and general A      IR were reduced by 41% (p = 
0.03) and 62% (p = 0.0005), respectively, while Thioflavin 
S amyloid was lowered by 38% (p = 0.06, trend) in immu-
nized mice when normalized to PBS control mice. Al-
though we measured total deposition, reductions in 
plaque load accounted for the majority of differences in 
immunized compared to control mice; vascular amyloid 
deposits were unchanged relative to the age-matched 
control mice. Semiquantitative analysis of vascular amy-
loid (scored 0–3) was similar in the hippocampus be-
tween PBS control and pE3-A      vaccinated mice (R1282: 
0.83   8   0.11 SEM vs. 0.75   8   0.13, p = 0.37; pE3-A    :  0.83 
  8   0.17 vs. 0.75   8   0.13, p = 0.41). In the cerebellum, vas-
cular amyloid was reduced by vaccination (R1282: 2.5   8  
0.19 vs. 2.5  8  0.15, p = 0.44; pE3-A   : 1.83  8  0.21 vs. 1.83 
Table 1. A  bsolute values of percent labeling within the area of in-
terest
PBS  A -pE3
vaccinated
Percent
reduction1
p
value
Prevention trial
Hippocampus
R1282 IR 13.080.06 10.680.88 18.2086.82 0.0119
pE3-A  0.6180.02 0.3980.10 35.33815.64 0.04
Thio S 0.7280.10 0.3680.06 49.5788.11 0.02
Cerebellum
R1282 IR 3.480.32 1.780.20 51.5685.96 0.005
pE3-A  0.3680.02 0.0980.02 75.5584.78 0.0004
Thio S 0.1780.06 0.180.02 43.49812.02 0.13
Therapeutic trial
Hippocampus
R1282 IR 10.080.76 7.580.66 24.8086.47 0.025
pE3-A  2.280.47 1.580.18 33.8487.90 0.11
Thio S 1.480.25 0.780.22 48.52814.25 0.04
Cerebellum
R1282 IR 3.980.29 1.580.27 62.3687.20 0.0005
pE3-A  1.080.14 0.680.09 40.9588.90 0.03
Thio S 0.7680.11 0.4780.06 38.3488.46 0.06
1  Percent reduction normalized to mean PBS control value.
pE3-A 
p
E
3
-
A
 
p
E
3
-
A
 
Thio S R1282
C
e
r
e
b
e
l
l
u
m
H
i
p
p
o
c
a
m
p
u
s
R
1
2
8
2
R
1
2
8
2
CB
d
R
O
I
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
0
**
n.s.
***
20
40
60
80
100
120
140
pE3-A  Thio S R1282
HC
b
c
a
R
O
I
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
0 200 μm
* * *
20
40
60
80
100
120
140
pE3-A  mAb
PBS
pE3-A  mAb
Prevention trial
PBS
200 μm
  Fig. 2. In a prevention study initiated dur-
ing the early stage of plaque deposition, 
weekly passive immunization of APPswe/
PS1     E9 mice with anti-pE3-A      mAb07/1 
from 5.8 to 13.8 months of age significant-
ly reduced pE3-A      as well as general A     
(R1282 IR) and fibrillar amyloid (Thiofla-
vin S) deposition in the hippocampus (  a , 
  b  ) and cerebellum (  c ,   d  ) compared to that 
in PBS control mice. Immunohistochemi-
cal results (  a ,   c  ) and Thioflavin S labeling 
were quantified by image analysis (  b ,   d ). 
Absolute values are provided in table 1. 
Scale bars, 200      m. p values:   *  p   !   0.05; 
  *  *  p   !   0.01;   *  *  *  p   !   0.001; n.s. = nonsig-
nificant (p = 0.089).  Passive  PyroGlu3-A     Immunotherapy in 
Mice 
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  8   0.17, p = 0.49). Microhemorrhages were not observed 
in either the immunized or control mice at 24.7 months 
of age.
  B i o c h e m i c a l  l e v e l s  o f  A    (x–42) and pE-A   (3–42) were 
slightly reduced with immunization but did not reach 
significance (data not shown). As in the prevention study, 
microgliosis and astrocytosis appeared to be lower in the 
immunized mice compared to the PBS control mice, pos-
sibly reflecting the reduced plaque burden.
  Discussion 
 APPswe/PS1    E9 mice showed increasing deposition 
of general A    ,  pE3-A    , and fibrillar amyloid in the cor-
tex, hippocampus and cerebellum with aging (i.e. from 
approx. 14 to 24.7 months of age), although pE3-A      was 
detected in much lower quantities at both ages compared 
to general A     . In this pilot study, using a small number 
of mice per group, passive immunization with a highly 
specific anti-pE3-A    mAb reduced all 3 types of deposits 
in the hippocampus and cerebellum in both a prevention 
study initiated in the early stage of plaque deposition and 
in a therapeutic study initiated in aged mice with robust 
A      deposition and gliosis. The percent of plaque reduc-
tion was similar between the prevention and the thera-
peutic trial, even though the absolute level of plaque de-
position was higher in the older mice. However, even in 
the therapeutic study, the absolute amount of general A     
and fibrillar amyloid deposits were reduced beyond the 
amount expected from clearance of pE3-A      deposits 
alone as shown in  table 1 , suggesting that pE3-A    remov-
al may prevent new plaque formation. In both studies, A    
deposit lowering by the pE3-A      mAb was greater in the 
cerebellum than the hippocampus (and the cortex, data 
not shown). This may be due, in part, to the lower abun-
dance of A      deposition in the cerebellum relative to that 
in the hippocampus and cortex. Possibly, plaque deposi-
tion in the cerebellum appears later or the antibodies had 
more access to the cerebellum than other brain regions. 
It is still unclear, though, why the biochemical measure-
ments of insoluble A     (x–42) and pE-A     (3–42) levels did 
not reflect the quantitative immunohistochemical re-
sults. Potential reasons are that the homogenates were de-
rived from entire hemibrains, but the pathological analy-
sis was done on small brain regions in thin sections, i.e. 
using a total of 3 equidistant brain sections per mouse. 
Moreover, different antibodies were used in the immuno-
histochemical and ELISA analyses, which may have con-
tributed to the discrepancy we observed. For example, the 
ELISAs used here quantify A     (x–42) and pE-A    (3–42), 
including low levels of P3 fragments, but not A      ending 
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  Fig. 3. In a therapeutic study initiated well 
after the onset of cerebral A      deposition 
and gliosis, weekly passive immunization 
with anti-pE3-A      mAb07/1 in 23-month-
old APPswe/PS1     E9 mice for 7 weeks re-
sulted in the attenuation of pE3-A      and 
general A      (R1282 IR) deposition as well 
as fibrillar amyloid (Thioflavin S) in the 
hippocampus (  a ,   b  ) and cerebellum (  c ,   d ) 
compared to PBS control mice. Immuno-
histochemical results (  a ,  c ) and Thioflavin 
S labeling were quantified by image analy-
sis (  b ,   d  ). Absolute values are provided in 
  table 1  . Scale bars, 200      m. p values:   *  p   !  
0.05;   *  *  *  p   !   0.001; n.s. = nonsignificant
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at residue 40. Immunohistochemistry was performed us-
ing R1282 pAb that detects general A      and mAb07/1 
(specific for A      starting at pyroglutamate at residue 3), 
both of which detect A      ending at residues 40 and 42. 
Lastly, interanimal variability and the low numbers of 
animals used in these preliminary studies may have 
played a role as well.
    Overall, our results confirm and extend those pub-
lished recently by Wirths et al.   [20]   in which 6 weeks of 
passive immunization with their IgG2b pE3-A      oligo-
mer-specific mAb, 9D5, led to reduced cerebral A    levels 
and plaque burden, and improved performance on the 
elevated plus maze test for anxiety in four 4.5-month-old 
5XFAD tg mice compared to 4 control mice. Plans are 
underway to study the effects of passive immunization 
with the anti-pE3-A      mAb07/1 used in our study (that 
recognizes monomeric, oligomeric and fibrillar pE3-A    ) 
on cognition, as well as AD pathogenesis, in a large co-
hort of AD-like tg mice.
    What are the implications of these studies? Selective 
removal of pE3-A      peptides, especially early in AD 
pathogenesis, may lower deposition of pE3-A    ,  general 
A     , and fibrillar amyloid, as pE3-A      may play a role in 
the aggregation and/or deposition of multiple A      species 
in brain. Therefore, selective targeting of this particular-
ly toxic A      species by immunotherapy may be an effec-
tive way to prevent or treat AD in humans in whom pE3-
A      IR is present in most, if not all, cerebral A      deposits. 